Status:

UNKNOWN

Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

Lead Sponsor:

Ain Shams University

Conditions:

Chronic Kidney Diseases

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The study aims to compare between the use of continuous low dose insulin infusion versus co-administration of low dose continuous insulin infusion and early subcutaneous insulin glargine in diabetic k...

Detailed Description

Diabetic ketoacidosis (DKA) is one of the most common and grave acute complications of diabetes and is a significant cause of morbidity and mortality. The current available guidelines state that the ...

Eligibility Criteria

Inclusion

  • Male and female patients.
  • Type I and type II diabetes mellitus.
  • Patients on insulin and/or oral hypoglycemic therapy.
  • Duration of diabetes more than 5 years.
  • Medical and surgical patients.

Exclusion

  • Severe persistent hypotension (SBP \<80 inspite of receiving 1000ml of normal saline).
  • Acute myocardial infarction.
  • Progressive renal failure or end stage renal disease defined as eGFR \< 15ml/min.
  • Liver cell failure.
  • Pregnancy.
  • Need for emergency surgery

Key Trial Info

Start Date :

December 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2022

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT05219942

Start Date

December 1 2020

End Date

July 1 2022

Last Update

June 7 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ain Shams University

Cairo, Egypt, 11566